|
1.
|
Chouaib S, Messai Y, Couve S, Escudier B,
Hasmim M and Noman MZ: Hypoxia promotes tumor growth in linking
angiogenesis to immune escape. Front Immunol. 3:1–10. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Wilson WR and Hay MP: Targeting hypoxia in
cancer therapy. Nat Rev Cancer. 11:393–410. 2011. View Article : Google Scholar
|
|
3.
|
Höckel M and Vaupel P: Tumor hypoxia:
definitions and current clinical, biologic and molecular aspects. J
Natl Cancer Inst. 93:266–276. 2001.PubMed/NCBI
|
|
4.
|
Melillo G: Inhibiting hypoxia-inducible
factor 1 for cancer therapy. Mol Cancer Res. 4:601–605. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
|
|
6.
|
Semenza GL: Involvement of
hypoxia-inducible factor 1 in human cancer. Intern Med. 41:79–83.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Giaccia A, Siim BG and Johnson RS: HIF-1
as a target for drug development. Nat Rev Drug Discov. 2:803–811.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Waldhauer I and Steinle A: NK cells and
cancer immunosurveillance. Oncogene. 27:5932–5943. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Nausch N and Cerwenka A: NKG2D ligands in
tumor immunity. Oncogene. 27:5944–5958. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Salih HR, Rammensee H-G and Steinle A:
Cutting edge: down-regulation of MICA on human tumors by
proteolytic shedding. J Immunol. 169:4098–4102. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Salih HR, Goehlsdorf D and Steinle A:
Release of MICB molecules by tumor cells: mechanism and soluble
MICB in sera of cancer patients. Hum Immunol. 67:188–195. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Waldhauer I and Steinle A: Proteolytic
release of soluble UL16-binding protein 2 from tumor cells. Cancer
Res. 66:2520–2526. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Boutet P, Agüera-González S, Atkinson S,
Pennington CJ, Edwards DR, Murphy G, Reyburn HT and Valés-Gómez M:
Cutting edge: the metalloproteinase ADAM17/TNF-α-converting enzyme
regulates proteolytic shedding of the MHC class I-related chain B
protein. J Immunol. 182:49–53. 2009.PubMed/NCBI
|
|
14.
|
Groh V, Wu J, Yee C and Spies T:
Tumour-derived soluble MIC ligands impair expression of NKG2D and
T-cell activation. Nature. 419:734–738. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Raffaghello L, Prigione I, Airoldi I,
Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S
and Pistoia V: Downregulation and/or release of NKG2D ligands as
immune evasion strategy of human neuroblastoma. Neoplasia.
6:558–568. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Märten A, von Lilienfeld-Toal M, Büchler
MW and Schmidt J: Soluble MIC is elevated in the serum of patients
with pancreatic carcinoma diminishing γδT cell cytotoxicity. Int J
Cancer. 119:2359–2365. 2006.PubMed/NCBI
|
|
17.
|
Lee CT, Mace T and Repasky EA:
Hypoxia-driven immunosuppression: a new reason to use thermal
therapy in the treatment of cancer? Int J Hyperthermia. 26:232–246.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Siemens DR, Hu N, Sheikhi AK, Chung E,
Frederiksen LJ, Pross H and Graham CH: Hypoxia increases tumor cell
shedding of MHC class I chain-related molecule: role of nitric
oxide. Cancer Res. 68:4746–4753. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Barsoum IB, Hamilton TK, Li X, Cotechini
T, Miles EA, Siemens DR and Graham CH: Hypoxia induces escape from
innate immunity in cancer cells via increased expression of ADAM10:
role of nitric oxide. Cancer Res. 71:7433–7441. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Postovit LM, Adams MA, Lash GE, Heaton JP
and Graham CH: Oxygen-mediated regulation of tumor cell
invasiveness. Involvement of a nitric oxide signaling pathway. J
Biol Chem. 277:35730–35737. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Postovit LM, Sullivan R, Adams MA and
Graham CH: Nitric oxide signalling and cellular adaptations to
changes in oxygenation. Toxicology. 208:235–248. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Postovit LM, Adams MA, Lash GE, Heaton JP
and Graham CH: Nitric oxide-mediated regulation of hypoxia-induced
B16F10 melanoma metastasis. Int J Cancer. 108:47–53. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Yoon SY, Lee YJ, Seo JH, Sung HJ, Park KH,
Choi IK, Kim SJ, Oh SC, Choi CW, Kim BS, Shin SW, Kim YH and Kim
JS: uPAR expression under hypoxic conditions depends on iNOS
modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma
cell line. Cell Res. 16:75–81. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Quintero M, Brennan PA, Thomas GJ and
Moncada S: Nitric oxide is a factor in the stabilization of
hypoxia-inducible factor-1alpha in cancer: role of free radical
formation. Cancer Res. 66:770–774. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Luo L, Lu J, Wei L, Long D, Guo JY, Shan
J, Li FS, Lu PY, Li PY and Feng L: The role of HIF-1 in
up-regulating MICA expression on human renal proximal tubular
epithelial cells during hypoxia/reoxygenation. BMC Cell Biol.
11:1–13. 2010.PubMed/NCBI
|
|
26.
|
Wei L, Lu J, Feng L, Long D, Shan J, Li S
and Li Y: HIF-1alpha accumulation upregulates MICA and MICB
expression on human cardiomyocytes and enhances NK cell
cytotoxicity during hypoxia-reoxygenation. Life Sci. 87:111–119.
2010. View Article : Google Scholar : PubMed/NCBI
|
